A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.
Also called NCT03131687
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 318 participants
- Sponsor
- Registry
-
NCT03131687 -
2016-004179-33
-
- Other papers using this trial's data
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Poland, Puerto Rico, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT03131687. Randomized; double masking; primary purpose treatment. Start 2017-05-24 (actual); primary completion 2018-08-01 (actual). Results posted on 2019-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- tirzepatide
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03131687- Content hash
1e2a21c1e56829a58735f53f7a0539655a428fcf9d1f5f8404dc773ac191046c